Dr. Hruz has clinical interest in a wide range of endocrine disorders, with a special interest in diabetes mellitus. Dr. Hruz's research interests include intermediary carbohydrate metabolism, glucose transporter structure and function and mechanism of insulin action. Currently, the mechanism(s) by which HIV protease inhibitors cause serious adverse metabolic effects including peripheral lipoatrophy, visceral adiposity, hypertriglyceridemia, and insulin resistance are being investigated. The laboratory has discovered that HIV protease inhibitors selectively and reversibly inhibit the GLUT4 facilitative glucose transporter. Ongoing studies are being directed toward elucidating the selectivity of these drugs in blocking the activity of each of the known facilitative glucose transport proteins. The tertiary structure of the facilitative glucose transporters is also being investigated using state-of-the-art biophysical approaches.
Standard shipping requests: Please notify us of pending shipments.
Hruz, P. W., Yan, Q., Tsai, L., Koster, J., Xu, L., Cihlar, T., Callebaut, C. (2011). GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system. Antimicrob Agents Chemother, 55 (4), 1377-82. PMCID: PMC3067185 PubMed: 21245443.
Hresko, R. C., Kraft, T. E., Tzekov, A., Wildman, S. A., Hruz, P. W. (2014). Isoform-selective Inhibition of Facilitative Glucose Transporters: Elucidation of the Molecular Mechanism of HIV Protease Inhibitor Binding. J Biol Chem, 289 (23), 16100-16113. PMCID: PMC4047383 PubMed: 24706759.
Vyas, A. K., Yang, K. C., Woo, D., Tzekov, A., Kovacs, A., Jay, P. Y., Hruz, P. W. (2011). Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One, 6 (2), e17178. PMCID: PMC3040766 PubMed: 21359201.
Paul Hruz Lab has not received any reviews.
Paul Hruz Lab has not received any endorsements.